ASH 2022 | Defining the optimal duration of maintenance therapy for multiple myeloma
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, discusses the importance of determining the optimal duration of maintenance therapy for multiple myeloma. Analysis from the Myeloma XI trial (NCT01554852) indicated that continuing maintenance therapy beyond three years is associated with improved overall survival (OS) and progression-free survival (PFS). Improvement is also observed beyond four years, however the impact of the maintenance therapy is slightly diminished. Future trials will continue to investigate into the optimal duration of these maintenance strategies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
